Analytica Limited designs, develops, and supplies medical devices in Australia, the United Kingdom, and the United States. More Details
Weak fundamentals or lack of information.
Share Price & News
How has Analytica's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ALT's share price has been volatile over the past 3 months.
7 Day Return
AU Medical Equipment
1 Year Return
AU Medical Equipment
Return vs Industry: ALT underperformed the Australian Medical Equipment industry which returned -1.4% over the past year.
Return vs Market: ALT underperformed the Australian Market which returned -12.4% over the past year.
Price Volatility Vs. Market
How volatile is Analytica's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StHow Should Investors React To Analytica's (ASX:ALT) CEO Pay?
3 months ago | Simply Wall StDoes Analytica Limited's (ASX:ALT) CEO Pay Matter?
4 months ago | Simply Wall StRead This Before Selling Analytica Limited (ASX:ALT) Shares
Is Analytica undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether Analytica is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Analytica has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
- Take a look at our analysis of ALT's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Analytica regulatory filings.
- Explore potentially undervalued companies in the Healthcare industry.
How is Analytica forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Analytica has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Take a look at our analysis of ALT’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Analytica competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
How has Analytica performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALT is currently unprofitable.
Growing Profit Margin: ALT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ALT is unprofitable, but has reduced losses over the past 5 years at a rate of 26.1% per year.
Accelerating Growth: Unable to compare ALT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALT is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (37.2%).
Return on Equity
High ROE: ALT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Analytica's financial position?
Financial Position Analysis
Short Term Liabilities: ALT has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: ALT has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: ALT has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: ALT's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ALT has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ALT has less than a year of cash runway if free cash flow continues to grow at historical rates of 19.5% each year.
What is Analytica current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ALT's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mr. Geoff Daly, BE (Hons, Mech, UQ), MBA (Exec, AGSM), MIEAust CPEng (Mech, Biomed), MAICD has been the Chief Executive Officer of Analytica Ltd. since February 12, 2014. Mr. Daly served as the Chief Opera ...
CEO Compensation Analysis
Compensation vs Market: Geoff's total compensation ($USD203.84K) is about average for companies of similar size in the Australian market ($USD276.97K).
Compensation vs Earnings: Geoff's compensation has increased whilst the company is unprofitable.
|Executive Chairman||16.25yrs||AU$82.13k||25.01% |
|CFO & Executive Director||11.92yrs||AU$192.72k||3.17% |
|Non-Executive Director||3.33yrs||AU$54.75k||no data|
Experienced Board: ALT's board of directors are seasoned and experienced ( 11.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Analytica Limited's company bio, employee growth, exchange listings and data sources
- Name: Analytica Limited
- Ticker: ALT
- Exchange: ASX
- Founded: 1985
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: AU$7.039m
- Shares outstanding: 3.52b
- Website: https://www.analyticamedical.com
Number of Employees
- Analytica Limited
- 320 Adelaide Street
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ALT||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Oct 2000|
|ALT||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Oct 2000|
Analytica Limited designs, develops, and supplies medical devices in Australia, the United Kingdom, and the United States. The company’s lead product is PeriCoach system, an e-health treatment system for w ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/22 19:04|
|End of Day Share Price||2020/09/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.